You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOsanetant
Accession NumberDB04872
TypeSmall Molecule
GroupsInvestigational
DescriptionDeveloped by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • SR 142801
  • SR-142801
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIK7G81N94DT
CAS number160492-56-8
WeightAverage: 606.625
Monoisotopic: 605.257582985
Chemical FormulaC35H41Cl2N3O2
InChI KeyInChIKey=DZOJBGLFWINFBF-UMSFTDKQSA-N
InChI
InChI=1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1
IUPAC Name
N-(1-{3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl)-N-methylacetamide
SMILES
CN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C2=CC=CC=C2)C2=CC(Cl)=C(Cl)C=C2)CC1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1-benzoylpiperidines. These are compounds containing a piperidine ring substituted at the 1-position with a benzoyl group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoyl derivatives
Direct Parent1-benzoylpiperidines
Alternative Parents
Substituents
  • 1-benzoylpiperidine
  • N-benzoylpiperidine
  • Phenylpiperidine
  • Phenylbutylamine
  • Piperidinecarboxylic acid
  • N-acyl-piperidine
  • Benzoic acid or derivatives
  • Benzamide
  • 1,2-dichlorobenzene
  • Aralkylamine
  • Halobenzene
  • Chlorobenzene
  • 4-aminopiperidine
  • Piperidine
  • Aryl halide
  • Aryl chloride
  • Acetamide
  • Tertiary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationPotential therapy for schizophrenia, depression and visceral pain.
PharmacodynamicsOsanetant is a neurokinin-3 (NK3) receptor antagonist. Preliminary clinical trials have demonstrated that osanetant is superior to placebo on global assessment of efficacy and measures of positive symptoms in schizophrenia.
Mechanism of actionThe mechanism of action of osanetant is uncertain at this point. Various preclinical data indicate that activation of NK3 receptors enhances the release of biogenic amines, including dopamine and serotonin. NK3 receptor antagonists could block NK3-receptor-mediated activation of these systems.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9486
Blood Brain Barrier+0.9882
Caco-2 permeable+0.5767
P-glycoprotein substrateSubstrate0.6866
P-glycoprotein inhibitor IInhibitor0.7694
P-glycoprotein inhibitor IIInhibitor0.837
Renal organic cation transporterInhibitor0.5525
CYP450 2C9 substrateNon-substrate0.8013
CYP450 2D6 substrateNon-substrate0.6861
CYP450 3A4 substrateSubstrate0.7427
CYP450 1A2 substrateNon-inhibitor0.9532
CYP450 2C9 inhibitorNon-inhibitor0.9439
CYP450 2D6 inhibitorInhibitor0.5109
CYP450 2C19 inhibitorNon-inhibitor0.8248
CYP450 3A4 inhibitorNon-inhibitor0.703
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7353
Ames testNon AMES toxic0.7977
CarcinogenicityNon-carcinogens0.8292
BiodegradationNot ready biodegradable0.994
Rat acute toxicity2.8030 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9523
hERG inhibition (predictor II)Inhibitor0.8584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000154 mg/mLALOGPS
logP6.47ALOGPS
logP6.27ChemAxon
logS-6.6ALOGPS
pKa (Strongest Basic)9.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.86 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity172.73 m3·mol-1ChemAxon
Polarizability66.11 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Kronenberg G, Berger P, Tauber RF, Bandelow B, Henkel V, Heuser I: Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry. 2005 Jan;38(1):24-9. [PubMed:15706463 ]
  2. Kamali F: Osanetant Sanofi-Synthelabo. Curr Opin Investig Drugs. 2001 Jul;2(7):950-6. [PubMed:11757797 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineOsanetant may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineOsanetant may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Osanetant.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Osanetant.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Osanetant.
adipiplonThe risk or severity of adverse effects can be increased when Osanetant is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Osanetant is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Osanetant is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Osanetant.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Osanetant.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Osanetant.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Osanetant.
AmisulprideThe risk or severity of adverse effects can be increased when Osanetant is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Osanetant.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Osanetant.
AmoxapineThe risk or severity of adverse effects can be increased when Osanetant is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Osanetant is combined with Amperozide.
AmphetamineOsanetant may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Osanetant.
ArticaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Osanetant is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Azaperone.
AzelastineOsanetant may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Osanetant.
BaclofenThe risk or severity of adverse effects can be increased when Osanetant is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Osanetant.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Osanetant.
BenzphetamineOsanetant may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Osanetant is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Osanetant is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.
BrimonidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Osanetant.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Osanetant.
BrompheniramineThe risk or severity of adverse effects can be increased when Osanetant is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Osanetant is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Osanetant.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Osanetant.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Osanetant.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Osanetant.
ButacaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Osanetant is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Osanetant is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Osanetant.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Osanetant.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Osanetant.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Osanetant.
CarbinoxamineThe risk or severity of adverse effects can be increased when Osanetant is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Osanetant.
CarisoprodolThe risk or severity of adverse effects can be increased when Osanetant is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Osanetant is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Osanetant.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Osanetant.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Osanetant.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Osanetant.
ChlorphenamineThe risk or severity of adverse effects can be increased when Osanetant is combined with Chlorphenamine.
ChlorphentermineOsanetant may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Osanetant.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Osanetant.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Osanetant.
CitalopramThe risk or severity of adverse effects can be increased when Osanetant is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Osanetant is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Osanetant is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Osanetant is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Osanetant is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Osanetant is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Osanetant is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Osanetant.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Osanetant.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Osanetant.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Osanetant.
CyclizineThe risk or severity of adverse effects can be increased when Osanetant is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Osanetant.
CyproheptadineThe risk or severity of adverse effects can be increased when Osanetant is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Osanetant is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Osanetant.
DapoxetineThe risk or severity of adverse effects can be increased when Osanetant is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Osanetant is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Osanetant.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Osanetant.
DesloratadineThe risk or severity of adverse effects can be increased when Osanetant is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Osanetant.
DetomidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Osanetant is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Osanetant.
DextroamphetamineOsanetant may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Osanetant.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Osanetant.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Osanetant.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Osanetant.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Osanetant.
DifenoxinThe risk or severity of adverse effects can be increased when Osanetant is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Osanetant.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Osanetant.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Osanetant.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Osanetant.
DimenhydrinateThe risk or severity of adverse effects can be increased when Osanetant is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Osanetant.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Osanetant.
DoramectinThe risk or severity of adverse effects can be increased when Osanetant is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Osanetant.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.
DoxylamineThe risk or severity of adverse effects can be increased when Osanetant is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Osanetant is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Osanetant.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Osanetant.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Osanetant.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Osanetant.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Osanetant.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Osanetant.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Osanetant.
EfavirenzThe risk or severity of adverse effects can be increased when Osanetant is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Osanetant.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Osanetant.
EntacaponeThe risk or severity of adverse effects can be increased when Osanetant is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Osanetant.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Osanetant.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Osanetant.
EscitalopramThe risk or severity of adverse effects can be increased when Osanetant is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Osanetant.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Osanetant.
EthanolOsanetant may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Osanetant.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Osanetant.
EthosuximideThe risk or severity of adverse effects can be increased when Osanetant is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Osanetant is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Osanetant.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Osanetant.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Osanetant.
EtidocaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Osanetant is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Osanetant is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Osanetant.
EtoperidoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Osanetant.
EzogabineThe risk or severity of adverse effects can be increased when Osanetant is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Osanetant is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Osanetant.
FenfluramineThe risk or severity of adverse effects can be increased when Osanetant is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Osanetant.
FexofenadineThe risk or severity of adverse effects can be increased when Osanetant is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Osanetant is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Osanetant.
FlunarizineThe risk or severity of adverse effects can be increased when Osanetant is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Osanetant.
FluoxetineThe risk or severity of adverse effects can be increased when Osanetant is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Osanetant.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Osanetant.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Osanetant.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Osanetant.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Osanetant is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Osanetant is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Osanetant is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Osanetant is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Osanetant.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Osanetant.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Osanetant is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Osanetant.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Osanetant.
GuanfacineThe risk or severity of adverse effects can be increased when Osanetant is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Osanetant.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Osanetant.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Osanetant.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Osanetant.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Osanetant.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Osanetant.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Osanetant.
Hydroxyamphetamine hydrobromideOsanetant may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.
HydroxyzineThe risk or severity of adverse effects can be increased when Osanetant is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Osanetant.
IndalpineThe risk or severity of adverse effects can be increased when Osanetant is combined with Indalpine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Osanetant.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Osanetant.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Osanetant.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Osanetant.
KetobemidoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Osanetant is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Osanetant is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Osanetant.
LevocabastineThe risk or severity of adverse effects can be increased when Osanetant is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Osanetant is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Osanetant is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Osanetant.
LevomilnacipranThe risk or severity of adverse effects can be increased when Osanetant is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Osanetant.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Osanetant.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Osanetant.
LisdexamfetamineOsanetant may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Osanetant.
LithiumThe risk or severity of adverse effects can be increased when Osanetant is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Osanetant is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Osanetant is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Osanetant.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Osanetant.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Osanetant.
Lu AA21004The risk or severity of adverse effects can be increased when Osanetant is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Osanetant.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Osanetant is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Osanetant.
MeclizineThe risk or severity of adverse effects can be increased when Osanetant is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Osanetant.
MelperoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Melperone.
MephentermineOsanetant may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Osanetant.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Osanetant.
MequitazineOsanetant may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Osanetant.
MetaxaloneThe risk or severity of adverse effects can be increased when Osanetant is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Osanetant.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Osanetant.
MethamphetamineOsanetant may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Osanetant.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Osanetant.
MethocarbamolThe risk or severity of adverse effects can be increased when Osanetant is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Osanetant.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Osanetant.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Osanetant.
MethsuximideThe risk or severity of adverse effects can be increased when Osanetant is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Osanetant is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Osanetant.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Osanetant.
MetyrosineOsanetant may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Osanetant.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Osanetant.
MilnacipranThe risk or severity of adverse effects can be increased when Osanetant is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Osanetant.
MirtazapineOsanetant may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Osanetant.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Osanetant.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Osanetant.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Osanetant.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Osanetant.
NabiloneThe risk or severity of adverse effects can be increased when Osanetant is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Osanetant.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Osanetant.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Osanetant.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Osanetant.
Nitrous oxideThe risk or severity of adverse effects can be increased when Osanetant is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Osanetant.
OlanzapineThe risk or severity of adverse effects can be increased when Osanetant is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Osanetant is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Osanetant.
OpiumThe risk or severity of adverse effects can be increased when Osanetant is combined with Opium.
OrphenadrineOsanetant may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Osanetant.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Osanetant.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Osanetant.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Osanetant.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Osanetant.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Osanetant.
ParaldehydeOsanetant may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Osanetant.
ParoxetineThe risk or severity of adverse effects can be increased when Osanetant is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Osanetant.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Osanetant.
PerampanelThe risk or severity of adverse effects can be increased when Osanetant is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Osanetant is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Osanetant.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Osanetant.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Osanetant.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Osanetant.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Osanetant is combined with Phenoxyethanol.
PhentermineOsanetant may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Osanetant is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Osanetant.
PipamperoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Osanetant is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Osanetant is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Osanetant is combined with Pomalidomide.
PramipexoleOsanetant may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Osanetant.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Osanetant.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Osanetant.
PrimidoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Osanetant.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Osanetant.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Osanetant.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Osanetant.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Osanetant.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Osanetant.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Osanetant.
PropoxycaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Osanetant.
PSD502The risk or severity of adverse effects can be increased when Osanetant is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Osanetant.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Osanetant.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Osanetant.
RamelteonThe risk or severity of adverse effects can be increased when Osanetant is combined with Ramelteon.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Osanetant.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Osanetant.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Osanetant.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Osanetant.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Osanetant.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Osanetant.
RomifidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Romifidine.
RopiniroleOsanetant may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Osanetant.
RotigotineOsanetant may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Osanetant.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Osanetant.
ScopolamineThe risk or severity of adverse effects can be increased when Osanetant is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Osanetant.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Osanetant.
SertindoleThe risk or severity of adverse effects can be increased when Osanetant is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Osanetant is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Osanetant.
Sodium oxybateThe risk or severity of adverse effects can be increased when Osanetant is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Osanetant is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Osanetant.
SulpirideThe risk or severity of adverse effects can be increased when Osanetant is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Osanetant.
SuvorexantThe risk or severity of adverse effects can be increased when Osanetant is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Osanetant.
TasimelteonThe risk or severity of adverse effects can be increased when Osanetant is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Osanetant.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Osanetant.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Osanetant.
TetracaineThe risk or severity of adverse effects can be increased when Osanetant is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Osanetant is combined with Tetrodotoxin.
ThalidomideOsanetant may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Osanetant.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Osanetant.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Osanetant.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Osanetant.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Osanetant.
TiagabineThe risk or severity of adverse effects can be increased when Osanetant is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Osanetant is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Osanetant is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Osanetant is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Osanetant.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Osanetant.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Osanetant.
TrazodoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Osanetant.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Osanetant.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Osanetant.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Osanetant.
TriprolidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Osanetant.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Osanetant.
VigabatrinThe risk or severity of adverse effects can be increased when Osanetant is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Osanetant is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Osanetant is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Osanetant is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Osanetant.
ZiconotideThe risk or severity of adverse effects can be increased when Osanetant is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Osanetant is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Osanetant.
ZolazepamThe risk or severity of adverse effects can be increased when Osanetant is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Osanetant.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Osanetant.
ZonisamideThe risk or severity of adverse effects can be increased when Osanetant is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Osanetant.
ZotepineThe risk or severity of adverse effects can be increased when Osanetant is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Osanetant.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Tachykinin receptor activity
Specific Function:
This is a receptor for the tachykinin neuropeptide neuromedin-K (neurokinin B). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinity of this receptor to tachykinins is: neuromedin-K > substance K > substance P.
Gene Name:
TACR3
Uniprot ID:
P29371
Molecular Weight:
52201.35 Da
References
  1. Tian G, Wilkins D, Scott CW: Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition. Mol Pharmacol. 2007 Mar;71(3):902-11. Epub 2006 Dec 15. [PubMed:17172464 ]
Comments
comments powered by Disqus
Drug created on October 20, 2007 04:46 / Updated on August 17, 2016 12:24